Illumina's Q2 Revenues Jump 29 Percent | GenomeWeb

This article has been updated from a previous version to include information from Illumina's Q2 earnings call.

NEW YORK (GenomeWeb) – Illumina's second quarter revenues rose 29 percent year over year, the company announced after the close of the market on Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.